Dynamis Therapeutics Inc.
Pharmaceuticals for diabetic nephropathy
You may also be interested in...
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
A new document from the US FDA details acceptable substitutions for COVID-19 testing components that may be difficult to come by. See what the regulatory agency said about it here.
The renamed Expert Panel for Cosmetic Ingredient Safety has its own website now, which includes the conflict of interest statement its members are expected to sign. The panel will meet virtually 8-9 June to consider a raft of ingredient reports in various stages of development at Cosmetic Ingredient Review.